Single-dose antifungal for people with HIV and positive cryptococcal blood test
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV infection (HIV-1).
- You are 15 years old or older.
- You can and are willing to sign informed consent (agree to take part).
- Your blood test for cryptococcal antigen (CRAG) is positive at a level of at least 1:160.
- You can attend regular clinic visits as the study requires.
- You have no known allergy to amphotericin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a shorter course of an antifungal drug (fluconazole) plus earlier HIV treatment is safe and works as well as the standard approach for people with HIV who have a low level of cryptococcal antigen in their blood. It aims to prevent a serious fungal infection from developing.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This trial tests a one-time high dose of an antifungal medicine (liposomal amphotericin B) combined with a standard HIV treatment (B/F/TAF) for people with HIV who also have talaromycosis, a serious fungal infection. The goal is to see if this approach is safe and effective.
This Phase 3 trial tests whether a high-dose form of amphotericin B made in tiny fat particles (liposomal amphotericin B) is safer and more effective for treating widespread Histoplasmosis in adults with HIV. It may help people who have a serious, whole-body infection caused by Histoplasma.
This trial compares two antifungal medicines to treat talaromycosis, a serious fungal infection common in people with HIV. It tests whether a shorter course of treatment with two medicines is as good as the standard approach, which may help reduce side effects and hospital time.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Hear when a new Cryptococcal Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.